Valeo Pharma, Inc. engages in the acquisitions, in-licensing or similar arrangements of patent protected, pharmaceutical products in specific therapeutic areas for the Canadian market. It focuses on injectable generic products. Its products include Onstryv, Synacthen,M-Eslon, Utrogestan, Ondansetron, and other hospital products. The company was founded by Steven Saviuk on March 27, 2003 and is headquartered in Kirkland, Canada.
CEO： Mr. Steven Saviuk
Market： Pink Market